Drug-Receptor Interactions
Signal Transduction
Agonist: a chemical signal that triggers a specific response
Antagonist: a chemical signal that blocks a specific response
may block receptor
may bind different receptor
Drug-receptor complex
Inactive (R) vs active (R*)
full vs partial agonist
Receptor Families
transmembrane ligand-gate ion channels
transmembrane G protein coupled receptors
unoccupied receptor does not interact with G protein → occupied receptor changes shape and interacts with G protein, G protein releases GDP and binds GTP → alpha subunit of G protein dissociates and activates adenylyl cyclase → when hormone is no longer present, the receptor reverts to its resting state, GTP on the alpha subunit is hydrolyzed to GDP, and adenylyl cyclase is deactivated
enzyme linked receptors
intracellular receptors
Advantages/Disadvantages
signal amplification
desensitization/down-regulation
Dose Response Relationship
increase dose = increase efficacy
potency
reference is EC50
50% of receptors occupied
can be related to duration of occupation
efficacy
reference is Emax
concentration is required to get to Emax
depends upon number of receptors occupied
requires receptors to be occupied and activated
increased dose does not equal increased effect
dependent upon kinetics of receptor binding or dissociation constant Kd
[DR]/[Rt] = [D]/Kd+[D]
[E]/[Emax] = [D]/Kd+[D]
Intrinsic Activity
full agonists
maximal biologic effect
mimics endogenous compound
binds to and activates the receptor
intrinsic activity = 1
partial agonists
0 < intrinsic activity < 1
reduced biologic effect
activity may interfere with other endogenous/exogenous activity
can be used to reduce a response
inverse agonists
stabilize receptor inactive (binds to and inactivates the receptor)
biologic activity < 0
Antagonists
competitive
binds to same site on receptor as agonist
Emax depends upon the Kd of both the agonist and antagonist
reduces potency (increases EC50) but Emax remains the same
irreversible
covalently binds to active site on receptor
reduces Emax, but potency (EC50) remains the same
allosteric
binds to a different site than the agonist
reduces Emax, but potency (EC50) remains the same
functional
binds to completely separate receptor
Quantal Dose-Response Relationships
therapeutic index
the range between effective does (ED50) and toxic dose (TD50)
TI= TD50/ED50
clinical usefulness
disease states can alter TI